touchCLINICAL PERSPECTIVES

Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies

Access to this content is not permitted for healthcare professionals based in the UK

Back to Home

This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from Eli Lilly and Company Limited.

This medical education is provided by touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Downloads
    Module 1 Slides
    Module 2 Slides 1
    Module 2 Slides 2
    Module 2 Summary
    Module 3 Slides 1
    Module 3 Slides 2
    Module 3 Summary
    Module 4 Slides
    Module 4 Summary
    Module 1 Slides
    Module 2 Slides 1
    Module 2 Slides 2
    Module 2 Summary
    Module 3 Slides 1
    Module 3 Slides 2
    Module 3 Summary
    Module 4 Slides
    Module 4 Summary
    Module 1 Slides
    Module 2 Slides 1
    Module 2 Slides 2
    Module 2 Summary
    Module 3 Slides 1
    Module 3 Slides 2
    Module 3 Summary
    Module 4 Slides
    Module 4 Summary
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Simona Sacco

    University of L’Aquila, Italy

    Simona Sacco is professor of neurology at the University of L’Aquila in Italy and director of the local clinical neurology and stroke unit. read more

    Prof. Sacco is author of more than 270 publications in the field of stroke and headache. She is the president elect of the European Stroke Organisation and second vice-president of the European Headache Federation (EHF). She is currently the chief editor for the Headache and Neurogenic Pain section in Frontiers in Neurology, associate editor for the Journal of Headache and Pain, assistant editor for Stroke and member of the editorial board of Neurology. She has chaired the EHF guideline on the use of monoclonal antibodies targeting the calcitonin gene-related peptide for migraine prevention, the EHF consensus on resistant and refractory migraine and the EHF consensus on triptan non-responders.

    Professor Simona Sacco discloses: Personal fees as speaker or advisor from Abbott, Allergan-AbbVie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, Novo Nordisk, Pfizer and Teva Pharmaceuticals. Research grants from Novartis. Fees for CME/education from Medscape, Neurodiem and Ology Medical Education.
    Ms Elena Ruiz de la Torre

    European Migraine & Headache Alliance, Valencia, Spain

    Ms Elena Ruiz de la Torre is a world-renowned patient advocate, researcher and executive director of the European Migraine & Headache Alliance.read more

    She tirelessly and passionately advocates for people living with headache disorders in the workplace and beyond, with her advocacy career beginning in Spain. She also co-led the creation of the World Headache and Migraine Alliance, a patient-led coalition open to patient groups around the world. She has co-authored several publications, and her list of current advocacy work is extensive, including the “My Migraine Voice” global survey, the European “Migraine at Work” and “Access to Care” surveys, and the “Migraine Matters” project.

    Ms Elena Ruiz de la Torre has no interests/relationships or affiliations to disclose in relation to this activity.
    Prof. Mamoru Shibata

    Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan

    Prof. Mamoru Shibata is professor of neurology at the Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. read more

    He obtained his PhD degree from Keio University Graduate School of Medicine in 2000 and conducted post-doctoral research into neurodegenerative disease at Harvard Medical School. He served as a trustee of the International Headache Society from 2015 to 2017. He currently chairs the Pan-Asian Committee of the American Headache Society, and is also actively involved in the Japanese Headache Society. His recent research interests include the biological and structural changes of trigeminal ganglion neurons in migraine pathogenesis, functional interactions between TRP channels, and cortical spreading depolarization biology.

    Professor Mamoru Shibata discloses: Honoraria for lectures from Amgen K.K., Daiichi Sankyo, Eli Lilly Japan and Otsuka Pharmaceutical.
    Prof. Christian Lampl

    Convent Hospital of the Brothers of Mercy, Linz, Austria

    Prof. Christian Lampl is head of the Department of Neurology at the Convent Hospital of the Brothers of Mercy in Linz, Austria, director of the Headache Medical Center, Linz, and chair of the Center of Integrative Medicine for Elderly at the Ordensklinikum Linz. read more

    He is the current president of the European Headache Federation (EHF) and also serves as an associate editor for the Journal of Headache and Pain (JHP). Prof. Lampl’s research is focused on the epidemiology and burden of headache; migraine aura as a possible risk factor for migraine headache; and headache, with a focus on elderly people. He has published numerous articles and contributed to several book chapters. Prof. Lampl is an ad hoc reviewer for journals such as Cephalalgia, JHP, Headache, Clinical Journal of Pain, Journal of Neurology and European Journal of Neurology.

    Professor Christian Lampl discloses: Advisory board and speaker fees from AbbVie, Lilly, Lundbeck, Novartis, Pfizer and Teva Pharmaceuticals; Consultancy fees from Lilly and Lundbeck; Grants for planning and conducting clinical trials from AbbVie, Lilly and Lundbeck.
    Dr Simy Parikh

    Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Dr Simy Parikh is an assistant professor of neurology and headache medicine specialist at the Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA. read more

    Dr Parikh is board certified in neurology by the American Board of Psychiatry and headache medicine by the United Council for Neurologic Subspecialties. Her specific interests in headache medicine include spontaneous spinal cerebrospinal fluid leak, migraine, and migraine and pregnancy, on which she has published several papers. Dr Parikh is a member of the American Academy of Neurology, American Headache Society and International Headache Society, and serves on the medical advisory board of the Spinal CSF Leak Foundation. She is also interested in medical education and is the programme director of the Advanced Headache Diagnosis and Management Certificate Program at Thomas Jefferson University.

    Dr Simy Parikh discloses: Advisory board fees from Pfizer (Nurtec MONITOR Pregnancy Registry).
    Back to Faculty
    touchNEUROLOGY touchNEUROLOGY
    Play ArrowPlay Video
    Play ArrowPlay Video
    Play ArrowPlay Video
    Play ArrowPlay Video
    Play ArrowPlay Video
    Play ArrowPlay Video

    touchCLINICAL PERSPECTIVES
    A modular programme that includes a variety of interviews with experts and a patient, as well as downloadable resources. Close

    Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies

    Addressing the burden of migraine: The role of anti-CGRP antibodies in practice

    After watching this activity, participants should be better able to:

    • Explain the impact of migraine on patient quality of life and the importance of prevention

    Recognizing the burden of migraine in daily life

    After watching this activity, participants should be better able to:

    • Explain the impact of migraine on patient quality of life and the importance of prevention

    Anti-CGRP antibodies for migraine prevention: Insights from real-world evidence

    After watching this activity, participants should be better able to:

    • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention

    Treatment failure in patients with migraine: Insights and guidance

    After watching this activity, participants should be better able to:

    • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention
    • Formulate a strategy for stopping and restarting anti-CGRP antibodies for migraine prevention

    Anti-CGRP antibodies for patients with migraine: Practical management

    After watching this activity, participants should be better able to:

    • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention
    • Formulate a strategy for stopping and restarting anti-CGRP antibodies for migraine prevention

    Using anti-CGRP antibodies for migraine prevention: Key learnings

    After watching this activity, participants should be better able to:

    • Explain the impact of migraine on patient quality of life and the importance of prevention
    • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention
    • Formulate a strategy for stopping and restarting anti-CGRP antibodies for migraine prevention

    Modules

    Time: 11:46

    Module 1 - Addressing the burden of migraine: The role of anti-CGRP antibodies in practice

    Time: 11:27

    Module 2 - Part 1 - Recognizing the burden of migraine in daily life

    Time: 07:06

    Module 2 - Part 2 - Anti-CGRP antibodies for migraine prevention: Insights from real-world evidence

    Time: 09:33

    Module 3 - Part 1 - Treatment failure in patients with migraine: Insights and guidance - Expert Interview

    Time: 09:00

    Module 3 - Part 2 - Anti-CGRP antibodies for patients with migraine: Practical management - Expert Interview

    Time: 17:07

    Module 4 - Using anti-CGRP antibodies for migraine prevention: Key learnings - Course Director wrap up

    Content to enrich this programme...

    CONFERENCE HUB

    Highlights from from a headache poster session at the European Academy of Neurology 2022, an interview with Dr Raquel Gil-Gouveia

    Go To Hub

    JOURNALS

    Journal article on improving the patient care pathway for headache disorders

    Go To Article

    CONFERENCE HUB

    AAN 2023: Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial

    Go To Hub

    CONFERENCE HUB

    AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine

    Go To Hub

    JOURNALS

    Journal Article on Photophobia in Migraine

    Go To Article

    CONFERENCE HUB

    AAN 2023: Significant reduction in migraine days with REN for migraine prevention: A double-blind randomized sham-controlled clinical trial

    Go To Hub

    CONFERENCE HUB

    EAN 2023: Prof. Peter Goadsby shares highlights in migraine

    Go To Hub

    Topics covered in this activity

    Headache Disorders
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 1000+ topical and insightful peer-reviewed journal articles
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from Eli Lilly and Company Limited.
    This medical education is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 31 October 2023

    Claim Credit
    touchCLINICAL PERSPECTIVES
    Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies

    You may also be interested in...

    touchCLINICAL PERSPECTIVES

    Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine

    GO TO HUB

    touchIN CONVERSATION

    A patient’s perspective: Best practice for shared decision making in the prevention and treatment of migraine

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Robert Shapiro, AHS 2021: COVID-19 Incidence and Mortality Among Individuals with Migraine

    GO TO HUB

    JOURNALS

    Cognitive Dysfunction During Migraine Attacks

    GO TO ARTICLE
    Naegel.png

    JOURNALS

    On the Brink of a New Era in Headache Medicine?

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from Eli Lilly and Company Limited.
    This medical education is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 31 October 2023

    Faculty
    Downloads
    Featured
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup